| Code | CSB-RA006047MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to trabikibart, developed for research targeting CSF2RB (Colony Stimulating Factor 2 Receptor Subunit Beta), also known as the common beta chain (βc). CSF2RB serves as a shared receptor component for GM-CSF, IL-3, and IL-5, playing a crucial role in hematopoietic cell differentiation, survival, and activation. This receptor subunit is essential for signal transduction in myeloid and eosinophil lineages, making it significant in inflammatory and immune responses. Dysregulation of CSF2RB-mediated signaling has been implicated in various conditions including autoimmune diseases, allergic inflammation, and hematologic disorders.
Trabikibart is a therapeutic antibody designed to modulate CSF2RB signaling pathways, particularly investigated for its potential in treating inflammatory conditions. This biosimilar provides researchers with a valuable tool for investigating βc-dependent cytokine signaling mechanisms, studying receptor-ligand interactions, and exploring therapeutic interventions in immune-mediated diseases. The antibody enables detailed examination of CSF2RB function in cellular models and supports translational research efforts aimed at understanding cytokine receptor biology and developing targeted immunomodulatory strategies.
There are currently no reviews for this product.